Search Results

Agricola

Record details

Editorial commentary.

• Authors : Jain, Hasmukh¹

Subjects: *DIFFUSE large B-cell lymphomas; *B cell lymphoma; *CHIMERIC antigen receptors

• Source: Indian Journal of Cancer. Apr-Jun2024, Vol. 61 Issue 2, p201-203. 3p.

Record details

Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study.

• Authors : Davidson, Marta B.¹ (AUTHOR); Rice, Alexandra² (AUTHOR); Stewart, Douglas³ (AUTHOR)

Subjects: *B cell lymphoma; *DIFFUSE large B-cell lymphomas; *CLINICAL trials

• Source: Leukemia & Lymphoma. Dec2022, Vol. 63 Issue 12, p2996-2999. 4p.

Record details

A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients.

• Authors : Jelicic, Jelena (AUTHOR); Juul‐Jensen, Karen (AUTHOR); Bukumiric, Zoran (AUTHOR)

Subjects: B cell lymphoma; PROGNOSTIC models; OVERALL survival

• Source: European Journal of Haematology. Jan2025, Vol. 114 Issue 1, p26-36. 11p.

Record details

Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma—Final Analysis.

• Authors : Maerevoet, Marie; Casasnovas, Olivier; Cartron, Guillaume

Subjects: THERAPEUTIC use of antineoplastic agents; PLATINUM compounds; CANCER relapse

• Source: Cancers; Aug2024, Vol. 16 Issue 15, p2672, 9p

Record details

Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials.

• Authors : Gong, Inna Y.¹ (AUTHOR); Aminilari, Mahmood² (AUTHOR); Landego, Ivan³ (AUTHOR)

Subjects: *B cell lymphoma; *DIFFUSE large B-cell lymphomas; *CHIMERIC antigen receptors

• Source: Leukemia & Lymphoma. Oct2023, Vol. 64 Issue 10, p1643-1654. 12p.

Record details

A systematic review and meta-analysis on utilizing anti-CD19 chimeric antigen receptor T-cell therapy as a second-line treatment for relapsed and refractory diffuse large B-cell lymphoma.

• Authors : Asghar, Kanwal; Zafar, Maryam; Holland, Eva

Subjects: DIFFUSE large B-cell lymphomas; B cell lymphoma; CLINICAL trials

• Source: Frontiers in Oncology; 2024, p1-10, 10p

Record details

AbbVie And Genmab A/S Present Two Data Analyses From Clinical Trials Show Epcoritamab Induces Durable Complete Reponses As Monotherapy And Combination Treatment In Patients With Diffuse Large B-Cell Lymphoma; Results From Arm 1 Of The EPCORE NHL-2 Trial Show Treatment With Epcoritamab Combination Led To An Overall Response Rate Of 100% And A Complete Response Rate Of 87% In High-Risk Patients With Previously Untreated Diffuse Large B-Cell Lymphoma.

• Source: Benzinga.com. 2024.

Record details

Two Data Analyses from Clinical Trials Show Epcoritamab DuoBody® CD3xCD20 Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma DLBCL.

• Source: Pharma Business Week. 2024, pages. 731

Record details

A machine learning approach in a monocentric cohort for predicting primary refractory disease in Diffuse Large B-cell lymphoma patients

• Authors : Detrait, Marie Y.; Warnon, Stéphanie; Lagasse, Raphaël

• Source: PLoS ONE. October 1, 2024, Vol. 19 Issue 10, e0311261

Record details